REMARKS

Currently claims 1-50 are pending. Applicants amend claims 14-25, 27-42, 44-46, and 49-50 to reduce the filing fee by, *inter alia*, removing multiple dependency. Claims 47-48 are cancelled as being inappropriate to US practice. Applicants amend the specification for purposes of adding the priority information. The attached Abstract has been placed on a separate sheet of paper according to US practice.

Respectfully submitted,

John L. Lemanowicz
Attorney for Applicant
Registration No. 37,380

Date:

GlaxoSmithKline Corporate Intellectual Property Five Moore Drive P.O. Box 13398 Research Triangle Park, NC 27709-3398

Phone: 919-483-8247 Facsimile: 919-483-7988